



Universiteit  
Leiden

The Netherlands

## **The role of ApoCI, LPL and CETP in plasma lipoprotein metabolism - studies in mice**

Hoogt, C.C. van der

### **Citation**

Hoogt, C. C. van der. (2006, November 28). *The role of ApoCI, LPL and CETP in plasma lipoprotein metabolism - studies in mice*. Retrieved from <https://hdl.handle.net/1887/5414>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/5414>

**Note:** To cite this publication please use the final published version (if applicable).

---

**PUBLICATIONS***Full Papers*

Berbée JFP, **Van der Hoogt CC**, Sundararaman D, Havekes LM, Rensen PCN: Severe hypertriglyceridemia in human *APOC1* transgenic mice is caused by apoCI-induced inhibition of LPL. *J Lipid Res* 2005;46:297-306.

**Van der Hoogt CC**, Berbée JFP, Espirito Santo SMS, Gerritsen G, Krom YD, Van der Zee A, Havekes LM, Willems van Dijk K, Rensen PCN. ApoCI directly inhibits LPL activity independent of the VLDL receptor and apoC-III in mice. *BBA Mol Cell Biol*. 2006;1761:213-220.

Berbée JFP, **Van der Hoogt CC**, Kleemann R, Schippers EF, Kitchens RL, Van Dissel JT, Bakker-Woudenberg IAJM, Havekes LM, Rensen PCN. Apolipoprotein CI Stimulates the Response to Lipopolysaccharide and Reduces Mortality in Gram-Negative Sepsis. *FASEB J*. 2006;20:2162-2164.

**Van der Hoogt CC\***, Westerterp M\*, De Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PCN. Cholesteryl ester transfer protein decreases HDL and severely aggravates atherosclerosis in *APOE\*3-Leiden* mice. *Arterioscler Thromb Vasc Biol* 2006; *In press*.

Post SM, Groenendijk M, **Van der Hoogt CC**, Fievet C, Luc G, Hoekstra M, Princen HMG, Staels B, Rensen PCN. Cholesterol 7 $\alpha$ -Hydroxylase Deficiency in Mice on an *APOE\*3-Leiden* Background Increases Hepatic ABCA1 Expression and HDL-Cholesterol. *Arterioscler Thromb Vasc Biol* 2006; *In press*.

**Van der Hoogt CC**, Espirito Santo SMS, Kypreos KE, Van Vlijmen BJM, Havekes LM, Willems van Dijk K, Rensen PCN. The hepatic clearance of VLDL in the absence of the three major apoE-recognizing receptors is dependent on LPL. *Submitted*.

Gerritsen G, **Van der Hoogt CC**, Schaap FG, Voshol PJ, Kypreos KE, Maeda N, Groen AK, Havekes LM, Rensen PCN, Willems van Dijk K. ApoE\*2-associated hyperlipidemia is ameliorated by increased levels of apoAV, but unaffected by apoCIII deficiency. *Submitted*.

**Van der Hoogt CC**, De Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HMG, Jukema JW, Havekes LM, Rensen PCN. Fenofibrate increases HDL cholesterol by reducing the expression of cholesteryl ester transfer protein. *Submitted*.

Berbée JFP, **Van der Hoogt CC**, De Haas CJ, Van Kessel KPM, Dallinga-Thie GM, Romijn JA, Havekes LM, Van Leeuwen HJ, Rensen PCN. Plasma apoCI correlates with increased survival in patients with severe sepsis. *Submitted*.

**Van der Hoogt CC\***, De Haan W\*, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HMG, Romijn JA, Jukema JW, Havekes LM, Rensen PCN. Atorvastatin increases HDL cholesterol by reducing cholesteryl ester transfer protein. *In preparation*.

\*Both authors contributed equally.

---

## Abstracts

Rensen PCN, **Van der Hoogt CC**, Pennings M, Van Berkel TJC, Biessen EAL: Targeted correction of apoE2 into apoE3 at the genomic level by chimeraplasty. *Circulation* 2001;104:II-234.

Rensen P, Berbée J, **Van der Hoogt C**, Gerritsen G, Van der Zee A, Sundararaman D, Willems van Dijk K, Havekes L: Apolipoprotein CI is a potent inhibitor of lipoprotein lipase *in vitro* and *in vivo*. *Atherosclerosis* 2003;4:229.

Berbée JF, Schippers EF, **Van der Hoogt CC**, Van Dissel JT, Bakker IA, Havekes LM, and Rensen PC: ApoCI improves the inflammatory response to LPS in mice and humans. *Arterioscler Thromb Vasc Biol* 2004;24:E-8 [New Investigator Award].

**Van der Hoogt CC**, Berbée JF, Gerritsen G, Krom YD, Van der Zee A, Havekes LM, Willems van Dijk K, and Rensen PCN: ApoCI impairs the lipolytic conversion of triglyceride-rich lipoproteins in mice. *Arterioscler Thromb Vasc Biol* 2004;24:E-56.

Rensen PCN, Berbée JFP, Schippers EF, **Van der Hoogt CC**, Van Dissel JT, Bakker-Woudenberg IAJM, Havekes LM. Apolipoproteins modulate inflammatory responses to LPS in rodents and humans: implications for sepsis. *J Endotoxin Res* 2004;10:293.

Berbée JFP, Schippers EF, **Van der Hoogt CC**, Van Dissel JT, Bakker-Woudenberg IAJM, Havekes LM, Rensen PCN: ApoCI augments the inflammatory response to LPS and correlates with improved infection-related survival in mice and humans. *J Endotoxin Res* 2004;10:321.

Princen HM, De Haan W, **Van der Hoogt CC**, Van den Hoogen CM, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC: Torcetrapib inhibits CETP, atorvastatin decreases it and both increase HDL in APOE\*3-Leiden.CETP transgenic mice. *Arterioscler Thromb Vasc Biol* 2006;26:E57.

Berbée JFP, Schippers EF, **Van der Hoogt CC**, Kitchens RL, Van Dissel JT, Bakker-Woudenberg IAJM, Havekes LM, Rensen PCN. Apolipoprotein CI stimulates the inflammatory response to lipopolysaccharide in mice and humans. *Atherosclerosis* 2006;7:227.

Westerterp M, **Van der Hoogt CC**, De Haan W, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PCN: CETP expression increases the (V)LDL/HDL ratio and severely aggravates atherosclerosis in APOE\*3-Leiden mice. *Atherosclerosis* 2006;7:489.

De Haan W, **Van der Hoogt CC**, Van den Hoogen CM, Dallinga-Thie GM, Princen HMG, Jukema JW, Havekes LM, Rensen PCN: Torcetrapib inhibits cholesteryl ester transfer protein and increases HDL in CETP.APOE\*3-Leiden transgenic mice. *Atherosclerosis* 2006;7:551.

**Van der Hoogt CC**, De Haan W, Westerterp M, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PCN: Fenofibrate increases HDL-cholesterol by reducing the expression of the cholesteryl ester transfer protein. *Atherosclerosis* 2006;7:560.